Breaking News, Collaborations & Alliances

George Medicines & Piramal Pharma Develop Hypertension Drug

The U.S. Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025.

Author Image

By: Charlie Sternberg

Associate Editor

George Medicines, a late-stage biopharma company, in partnership with Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO), has developed WIDAPLIK, a new drug for the treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure. WIDAPLIK is a single pill combination of three medicines—telmisartan, amlodipine, and indapamide—for the treatment of hypertension, developed in three doses (10/1.25/0.625 mg, 20/2....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters